Valneva SE (INRLF) Stock Analysis

Valneva SE (INRLF) Healthcare & Pipeline Overview

Valneva SE is a specialty vaccine company focused on developing and commercializing prophylactic vaccines against infectious diseases with unmet needs, including Japanese encephalitis and chikungunya. With a global presence and a diverse pipeline of vaccine candidates, Valneva aims to address significant public health challenges and expand its market reach in the biotechnology sector.

What Is the Investment Thesis for INRLF?

Valneva SE presents a notable research candidate within the biotechnology sector, driven by its established vaccine portfolio and promising pipeline of vaccine candidates. The company's existing commercialized vaccines, including IXIARO and DUKORAL, generate revenue and provide a foundation for future growth. The recent approval of IXCHIQ/VLA1553 for chikungunya represents a significant milestone and a potential revenue stream. Valneva's Lyme disease vaccine candidate, VLA15, is a key value driver, addressing a substantial unmet need in a growing market. The company's negative P/E ratio of -7.22 reflects its investment in R&D and clinical trials, which could yield substantial returns upon successful product launches. However, potential risks include clinical trial setbacks, regulatory hurdles, and competition from established pharmaceutical companies.

Based on FMP financials and quantitative analysis

INRLF Key Highlights

Market capitalization of $624M reflects investor valuation of Valneva's current and future potential.

• Gross margin of 45.4% indicates efficient vaccine production and pricing strategies.
• Negative profit margin of -56.8% reflects ongoing investments in research and development for future growth.
• Beta of 1.27 suggests higher volatility compared to the overall market, typical for biotechnology companies.
• Valneva's diverse vaccine pipeline targets multiple infectious diseases, reducing reliance on a single product.

Who Are INRLF's Competitors?

INRLF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are INRLF's Key Strengths?

Diverse portfolio of commercialized vaccines and vaccine candidates.

• Specialized expertise in vaccine development and manufacturing.
• Established distribution networks in key markets.
• Proprietary vaccine technologies and intellectual property.

What Are INRLF's Weaknesses?

Negative profit margin due to high R&D expenses.

• Reliance on regulatory approvals for new vaccine launches.
• Competition from established pharmaceutical companies.
• Limited financial resources compared to larger competitors.

What Could Drive INRLF Stock Higher?

Clinical trial results for VLA15 (Lyme disease vaccine candidate) expected in late 2026.

• Commercialization and distribution of IXCHIQ/VLA1553 for chikungunya.
• Expansion of existing vaccine sales in key geographic markets.
• Regulatory approvals for new vaccine candidates in the pipeline.
• Strategic partnerships and collaborations to accelerate vaccine development.

What Are the Key Risks for INRLF?

Financial-distress signal — its Altman Z-Score of -1.91 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures and regulatory setbacks.
• Competition from established pharmaceutical companies.
• Changes in government regulations and reimbursement policies.
• Negative profit margin due to high R&D expenses.
• Product liability claims and litigation.

What Are the Growth Opportunities for INRLF?

• Expansion of IXCHIQ/VLA1553 for Chikungunya: Valneva's IXCHIQ vaccine, targeting the chikungunya virus, represents a significant growth opportunity. The single-dose nature of the vaccine offers a competitive advantage, simplifying administration and improving patient compliance. Successful commercialization and distribution of IXCHIQ could drive substantial revenue growth for Valneva.
• Advancement of Lyme Disease Vaccine Candidate (VLA15): Valneva's VLA15 vaccine candidate against Lyme disease is a key growth driver, targeting a market with increasing prevalence and limited treatment options. The vaccine has the potential to generate significant revenue upon approval, addressing a substantial unmet need. Positive clinical trial results and regulatory approvals would be major catalysts for Valneva's growth in the coming years.
• Development of Vaccine Candidates for Emerging Infectious Diseases: Valneva's pipeline includes vaccine candidates targeting emerging infectious diseases such as Zika virus, human metapneumovirus, Clostridium difficile, and Epstein-Barr virus. These programs represent long-term growth opportunities, positioning the company to address future public health threats. Successful development and commercialization of these vaccines could drive substantial revenue growth and enhance Valneva's reputation as an innovator in the vaccine space.
• Geographic Expansion into New Markets: Valneva has the opportunity to expand its geographic presence into new markets, particularly in Asia and Latin America, where the prevalence of infectious diseases is high. By establishing partnerships and distribution networks in these regions, Valneva can increase its market reach and drive revenue growth. This expansion strategy aligns with the company's mission to address global health challenges and improve access to vaccines worldwide.
• Strategic Partnerships and Collaborations: Valneva can leverage strategic partnerships and collaborations to accelerate the development and commercialization of its vaccine candidates. Collaborating with other pharmaceutical companies, research institutions, and government agencies can provide access to funding, expertise, and resources, enhancing Valneva's capabilities and reducing its financial risk. These partnerships can also facilitate the expansion of Valneva's product portfolio and market reach.

What Threats Does INRLF Face?

• Clinical trial failures and regulatory setbacks.
• Competition from biosimilars and generic vaccines.
• Changes in government regulations and reimbursement policies.
• Economic downturns and reduced healthcare spending.

What Are INRLF's Competitive Advantages?

• Specialized expertise in vaccine development and manufacturing.
• Proprietary vaccine technologies and intellectual property.
• Established distribution networks and partnerships.
• Regulatory approvals and market exclusivity for commercialized vaccines.

What Does INRLF Do?

Valneva SE, founded in 1998 and headquartered in Saint-Herblain, France, is a specialty vaccine company dedicated to developing, manufacturing, and commercializing prophylactic vaccines for infectious diseases with significant unmet medical needs. The company's mission is to leverage its expertise in vaccine development to address global health challenges and improve the lives of people worldwide. Valneva's commercialized product portfolio includes IXIARO, a vaccine against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholerae; and IXCHIQ/VLA1553, a single-dose vaccine for chikungunya. In addition to its commercial products, Valneva has a robust pipeline of vaccine candidates targeting diseases such as Lyme disease (VLA15), shigellosis (S4V2), Zika virus (VLA1601), human metapneumovirus (VLA1554), Clostridium difficile infection (VLA84), and Epstein-Barr virus (VLA2112). Valneva distributes its vaccines across the United States, Canada, Germany, Austria, the Nordics, the United Kingdom, France, the rest of Europe, and other international markets.

What Products and Services Does INRLF Offer?

• Develops and commercializes prophylactic vaccines for infectious diseases.
• Offers IXIARO, a vaccine against Japanese encephalitis.
• Provides DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera.
• Markets IXCHIQ/VLA1553, a single-dose vaccine for chikungunya.
• Develops VLA15, a vaccine candidate against Lyme disease.
• Creates vaccine candidates for Zika virus, human metapneumovirus, and other infectious diseases.
• Sells its products in the United States, Canada, Europe, and internationally.

How Does INRLF Make Money?

• Develops and manufactures vaccines for infectious diseases.
• Generates revenue through the sale of commercialized vaccines.
• Out-licenses vaccine technologies and forms strategic partnerships.
• Receives funding through government grants and research collaborations.

What Industry Does INRLF Operate In?

Valneva operates within the biotechnology industry, which is characterized by high growth potential and significant investment in research and development. Valneva competes with established pharmaceutical companies and other biotechnology firms in the development and commercialization of vaccines. The company's focus on specialty vaccines for unmet needs differentiates it from competitors and positions it for growth in niche markets.

Who Are INRLF's Key Customers?

• Travelers visiting regions where Japanese encephalitis, cholera, or chikungunya are prevalent.
• Military personnel deployed to areas with high risk of infectious diseases.
• Individuals living in or traveling to areas endemic for Lyme disease.
• Government agencies and public health organizations.

Valneva SE (INRLF) Valuation Context

Valued at $624M, INRLF is classified as a small-cap stock.

INRLF Revenue & Earnings Trend

In Q2 FY2026, INRLF generated $40.5M in top-line revenue, marking a sequential increase of 12.5%. The company recorded a net loss of $36.1M, with diluted EPS of $-0.19. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, INRLF averaged $-0.27 in diluted EPS.

Company Profile

Valneva SE operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Saint-Herblain, FR. The company is led by CEO Thomas Lingelbach. INRLF has traded publicly since 2010.

Key Financial Metrics

Return on assets is -37.1%, showing how much profit it generates from its asset base. Its free cash flow yield is -16.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.14 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -35.6%, the inverse of the P/E and a quick read on earnings relative to price.

Valneva SE's Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -1.91 places it in the distress zone, a signal of elevated financial risk.

Valneva SE has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 67.9% below estimates on average.

INRLF Financials

INRLF Latest News

INRLF Analyst Consensus

INRLF MoonshotScore

What Investors Ask About Valneva SE (INRLF) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources